Antidiabetic therapies affect risk of pancreatic cancer.
about
Advances in pancreatic cancer research: moving towards early detectionThe Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic CancerPancreatic Cancer Metabolism: Breaking It Down to Build It Back UpDiabetes and cancer: two diseases with obesity as a common risk factorIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseMechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cellsMetformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewMetformin: Current knowledgeMetformin and the risk of cancer: time-related biases in observational studiesCancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysisCellular and molecular mechanisms of metformin: an overviewMetformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated MacrophagesNew insights into pancreatic cancer-induced paraneoplastic diabetesManagement of pancreatogenic diabetes: challenges and solutionsMetformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expressionLow concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer actionMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugResponse of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combinedDose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer CellsType 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.Environmental risk factors for pancreatic cancer: an update.Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Is dynamic autocrine insulin signaling possible? A mathematical model predicts picomolar concentrations of extracellular monomeric insulin within human pancreatic islets.Latest insights into the risk of cancer in diabetesMetformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studiesImpact of diabetes mellitus on the outcome of pancreatic cancer.Diabetes medications and cancer risk: review of the literatureNeoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan.Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancerIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisThe effect of metformin on survival of patients with pancreatic cancer: a meta-analysisGlycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway.Chemoprevention strategies for pancreatic cancerTherapeutic options for the management of pancreatic cancer.
P2860
Q24563998-E4F975B8-B51F-449A-B7A3-FDF790C0F730Q26738873-9353DDC5-1CA1-49CC-A79B-C13092E523B9Q26780372-9F83B71F-32A5-4AC8-86E1-E7990204CECDQ26822753-18453961-035B-4587-B167-DC4B0E42C60BQ26827183-34865568-6748-4CFE-81D1-BECA8E980DD9Q26827387-C5C114E7-8923-4B27-8416-5D0A17C2566AQ26850912-3179EC13-A33A-41AE-87D8-E2FAEBCB666CQ26853666-14EBAEDE-F45B-417D-8063-2F0E31D99B67Q26999266-659352C8-CDB9-44EB-91AF-7580893BA883Q27002540-D7A59A70-DBB1-400D-97D9-0E38594A5DB3Q27013561-2EA152F6-E5D3-4C77-9ACE-E1B0259DE3D6Q27348974-8DADE412-607A-446B-B045-C13A4B01EA8FQ27687766-2B2DC62A-36C4-4417-8236-DE1163D0E28EQ28069386-4F429146-297B-45DC-B067-FAC18943F57FQ28478148-83E07A89-7C33-45F5-B456-91F13C48B235Q28487772-30D065E5-7FD7-4E68-A713-EB3ACE5936B0Q28538155-BE40B81C-F487-49C7-B473-E7BDA2DA1D48Q28539523-7498BFE0-6A35-4E69-928A-8A24632700BFQ28542653-77265B29-B9EA-41B6-B5A0-7430BB62B137Q30234827-D2062708-264C-4186-9C96-C320F70CE673Q30248417-CC725A88-7F60-4CF5-8AB9-519393D5A382Q30513617-D7D2900E-F35D-404B-A581-A4DC4CDE7460Q31119931-B750DC5A-66A6-456E-8461-2CC0E793F31FQ33588852-DDFC8536-5B0C-4ADD-A213-681A9F78762CQ33602223-6BFD2F80-0E00-4278-9219-052603B5C91BQ33648824-DEAEA053-C60C-4AD6-AFAC-CDD2388455DEQ33688699-8A29EE40-9937-43CC-9329-731AE4AF8B38Q33690094-7ED499F6-D7EF-4394-8619-F1415C3D366CQ33714881-267C2F59-98A9-4874-B022-9419E2E9DC7FQ33751263-62C74DEB-0680-4109-8DF5-98613226C30CQ33756122-F7DF737D-5B74-419D-9CEE-2067861B6762Q33795313-7B19DE19-1665-4A13-8811-2EF905DC4CA1Q33820455-6A72C3F8-A6F3-4187-858C-41A0E39CE2E8Q33880174-624ED0FA-6C15-463A-A29A-E8C41359011DQ33919105-D05B6E21-970A-465E-8763-75020D0ADDA7Q33935606-D7C056FD-4928-4C2E-9DBF-E4AE7314D66CQ33946957-AD6D563D-A66C-4433-8D38-DE9B9B60346FQ34040261-FDDE9ACB-A8F0-4A31-994A-9443C7F2596CQ34082960-B904AD2E-14F4-4F03-ABF4-4EDC2EE5B2EEQ34093776-77986F5E-F0BF-40F4-BBF7-6156B1673C87
P2860
Antidiabetic therapies affect risk of pancreatic cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antidiabetic therapies affect risk of pancreatic cancer.
@ast
Antidiabetic therapies affect risk of pancreatic cancer.
@en
Antidiabetic therapies affect risk of pancreatic cancer.
@nl
type
label
Antidiabetic therapies affect risk of pancreatic cancer.
@ast
Antidiabetic therapies affect risk of pancreatic cancer.
@en
Antidiabetic therapies affect risk of pancreatic cancer.
@nl
prefLabel
Antidiabetic therapies affect risk of pancreatic cancer.
@ast
Antidiabetic therapies affect risk of pancreatic cancer.
@en
Antidiabetic therapies affect risk of pancreatic cancer.
@nl
P2093
P2860
P1433
P1476
Antidiabetic therapies affect risk of pancreatic cancer.
@en
P2093
Donghui Li
James L Abbruzzese
Manal M Hassan
Sai-Ching J Yeung
P2860
P304
P356
10.1053/J.GASTRO.2009.04.013
P407
P577
2009-04-16T00:00:00Z